U-M Institutional Biosafety Committee
Minutes
Approved at the October 16, 2026, IBC Meeting

Meeting Information:

Date: Friday, September 18, 2026
Time: 1:15-2:30 p.m.
Location: Via conference call (Zoom)

Voting Members Present: Pamela Bennett-Baker, Matt Chapman, Steven Clark, Wanlu Du, Chris Fenno, Sheya Jones, Huira Kopera, Patrick Lester, Jon Oscherwitz, Stephen Rapundalo, Alex Rickard, Jackie Shields, Yifan Wang, Fei Wen, Christiane Wobus (Chair)

Voting Members Absent: Joyce Lai, Tom Lanigan, Jonny Sexton, Andrew Tai

Alternate Members Present: Jessica Bunn (alt. for Jones), Crystal O'Donnell (alt. for Jones), Janet Follo (alt. for Jones)

IBC Staff Members Present: Jen Harley, Michael Santiago-Castro, Alicia Trombley

Guests Present: Eric Robertson, Nicoleen Boyle, Kathy Ignatoski, Pat Ward, Sarah Lawson, Tyler Loveall, Kelli Christman

The meeting was called to order at: 1:15 p.m.
The meeting was adjourned at: 1:36 p.m.

Agenda Items:

1. Updates from the Chair – Christiane Wobus

Dr. Wobus introduced Tyler Loveall who will represent OGC at IBC meetings going forward.

2. Consideration of minutes from the previous meeting

The committee reviewed the minutes from the August 21, 2026, meeting. There were no changes recommended.

> **Motion:** Sheya Jones moved to approve the minutes.
> **Second:** Matt Chapman seconded the motion.
> **Vote:** All in favor.

3. Biosafety Officer Report – Sheya Jones

Ms. Jones reminded attendees of the U.S. Customs & Border Protection Importation of Biological Materials Workshop to be held on September 23, 2026.

4. Conflict of interest disclosure opportunity

Dr. Wobus asked committee members whether they or their labs were involved with, or were in conflict with, financially or otherwise, any items on today's agenda.

1. Huira Kopera indicated a conflict with application IBCA0000011_AR11 for Dr. Lanigan.

5. Applications for committee action

BSL2 Applications

The following BSL2 applications were considered and voted upon separately by the committee due to a conflict of interest.

13. IBCA00000724_AR06
Lanigan, Thomas - Vector Core – Renewal
Current approval: BSL1 (vectorless systems, plasmid, cosmid vectors); BSL2 (adenoviral, retroviral, AAV, yellow fever, and rabies viral vectors); BSL2 (Influenza virus and Porcine Respiratory Corona Virus); BSL2 (human-derived substances); BSL1 (animal-derived substances: swine). No work involving biological toxins, animals or plants.
Changes: Updated work with non-recombinant viruses (BSL1 and BSL2) and animal-derived substances (BSL1 and BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon favorable re-review from one reviewer.

> **Motion:** Stephen Rapundalo moved to approve the (1) applications listed above, at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.
> **Second:** Steven Clark seconded the motion.
> **Vote:** All in favor, with Huira Kopera recused.

The following BSL2 applications were considered by the committee and voted upon:

BSL2 Applications
1. IBCA00000008_AR09
Weinberg, Jason – Amendment
Current approval: BSL1 (plasmid and mouse adenovirus vectors); BSL1 (RG1 viruses); BSL2 (RG2 viruses and bacteria); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL2 for the duration (mice administered RG1/RG2 infectious agents). No work involving animal-derived substances or plants.
Changes: Added new gene elements in mouse adenovirus vectors (BSL1) and administration of mouse adenovirus vectors to mice (ABSL2 for the duration).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate.

2. IBCA00000033_AR16
Wong, Sunny – Amendment
Current approval: BSL1 (plasmid and AAV vectors; vectorless systems); BSL2 (lentivirus, MSCV, and adenovirus vectors); BSL2 (Staphylococcus aureus (MRSA)); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered plasmid vectors, AAV vectors, or rDNA-modified animal cells); ABSL2 for 3 days (mice administered adenovirus vectors); ABSL2 for the duration (mice administered human-derived substances, rDNA-modified human-derived substances, or Staphylococcus aureus (MRSA)). No work involving biological toxins, animal-derived substances, or plants.
Changes: Added administration of vectorless systems to mice (ABSL1).
Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

3. IBCA00000046_AR22
Lauring, Adam – Amendment
Current approval: BSL1 (plasmid vectors); BSL2 (plasmid, MoLV, lentivirus, rabies, vaccinia/pox, poliovirus, human and murine enterovirus, influenza A virus, RSV, and rotavirus viral vectors); BSL2 (RG2 viruses, Influenza H5 HPAI); BSL2 (human-derived substances); BSL2 (animal-derived substances: swine, ruminants, fowl, and wild vertebrate animals). No work involving biological toxins, animals or plants.
Changes: Added work with seasonal influenza viruses (BSL2) and updated work with animal-derived substances (BSL2).
Update for September agenda: Updated genetic elements (BSL2).
Consensus: The committee agreed with the reviewers' risk assessment that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. This project was also reviewed and approved by our Institutional Review Entity.

4. IBCA00000081_AR11
Nemzek, Jean – Amendment
Current approval: BSL1 (RG1 bacteria and virus); BSL2 (RG2 bacteria); BSL2 (LPS); BSL2 (human- and animal-derived substances from swine); ABSL1 (transgenic mice); ABSL1 (mice administered LPS); ABSL2 for the duration (mice administered pathogenic E. coli; pigs administered Staphylococcus aureus). No work involving rDNA or plants.
Changes: Added work with additional RG2 bacterial (BSL2), animal-derived substances from cows and sheep (BSL2), administration of MRSA to pigs (ABSL2 for the duration), and updated risk mitigation practices.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

5. IBCA00000214_AR11
Todd, Peter – Amendment
Current approval: BSL1 (vectorless systems, plasmid and AAV vectors); BSL2 (lentiviral vectors and AAV vectors with growth control genes); BSL2 (human- and animal-derived substances from non-human primates); ABSL1 (transgenic mice and fruit flies); ABSL1 (mice administered AAV vectors or vectorless systems); ABSL2 for 3 days (mice administered AAV vectors with growth control genes). No work involving infectious agents, biological toxins, or plants.
Changes: Added work with Tetrodotoxin (BSL2) and additional human-derived substances (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon favorable review by two reviewers and a meeting between the lab and EHS to further discuss the proposed toxin work.

6. IBCA00000316_AR06
Freddolino, Lydia – Amendment
Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (plasmid vectors in RG2 host); BSL2 (E. coli (pathogenic strains) and Vibrio cholera). No work involving biological toxins, human- or animal-derived substances, animals or plants.
Changes: Added work with Mycobacterium bovis (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

7. IBCA00000409_AR03
Meeker, John – Renewal
Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.
Changes: Updated work with human-derived substances (BSL2), and risk mitigation practices (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon favorable re-review from one reviewer.

8. IBCA00000484_AR14
Zou, Weiping – Amendment
Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (adenoviral, MSCV, MoLV, and lentiviral vectors); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered LPS or rDNA-modified animal cells); ABSL2 for the duration (mice administered adenoviral vectors, human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, animal-derived substances, or plants.
Changes: Added administration of vectorless systems to mice (ABSL1).
Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

9. IBCA00000494_AR05
Morgan, Meredith – Amendment
Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (MoLV and lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA-modified animal cells); ABSL2 for 3 days (mice administered rDNA-modified animal cells); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Added work with additional human-derived substances (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

10. IBCA00000561_AR07
Frankel, Timothy – Renewal
Current approval: BSL1 (plasmid vectors); BSL2 (lentivirus vectors); BSL2 (Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered Diphtheria toxin); ABSL2 for the duration (mice administered human-derived substances). No work involving infectious agents, animal-derived substances, or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable review by two reviewers and favorable re-review from one reviewer.

11. IBCA00000566_AR09
Kao, John – Amendment
Current approval: BSL1 (plasmid vectors); BSL2 (adenovirus and lentivirus vectors); BSL2 (RG2 bacteria and Toxoplasma gondii); BSL2 (Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered Diphtheria toxin); ABSL2 for the duration (mice administered rDNA modified animal cells, RG2 bacteria, and Toxoplasma gondii).

Changes: Added administration of human-derived substances to mice (ABSL2 for the duration).
Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

12. IBCA00000583_AR14
Hankenson, Kurt – Amendment
Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (adenovirus and lentivirus vectors); BSL2 (human-derived substances); BSL1 (animal-derived substances: ruminants and swine); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems); ABSL2 for 3 days (mice administered adenovirus vectors); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, or plants.
Changes: Added work with AAV vectors (BSL1).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. Approval is contingent upon minor edits being made to the application.

13. *This application was handled separately due to a conflict of interest*.

14. IBCA00000739_AR08
Aguilar, Carlos – Renewal
Current approval: BSL1 (AAV and baculovirus vectors); BSL2 (SIV and AAV vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Added work with plasmid vectors (BSL1). Changed the biosafety level for work with AAV vectors to BSL1. Removed work with baculovirus and SIV vectors and updated research goals with human-derived substances.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable review from one reviewer.

15. IBCA00000770_AR04
Pasca Di Magliano, Marina – Renewal
Current approval: BSL1 (plasmid vectors); BSL2 (Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA-modified animal cells or Diphtheria toxin); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances).
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

16. IBCA00000850_AR10
Prasov, Lev – Renewal
Current approval: BSL1 (vectorless systems, AAV, cosmid, and plasmid vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances); BSL1 (animal-derived substances from ruminants and swine); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, lentivirus, or AAV vectors). No work involving infectious agents, biological toxins, or plants.

Changes: Added work with MoLV vectors (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application, favorable review from one reviewer, and favorable re-review by one reviewer.

17. IBCA00000886_AR06
Brooks Herzog, Susan – Renewal
Current approval: BSL2 (human-derived substances); BSL1 (animal-derived substances: ruminants and swine); ABSL1 (transgenic mouse). No work involving rDNA, infectious agents, biological toxins, or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

18. IBCA00000913_AR03
Kitzman, Jacob – Renewal
Current approval: BSL1 (plasmid vectors); BSL2 (lentivirus vectors); BSL2 (human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, animals or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

19. IBCA00000963_AR06
Pearring, Jillian – Renewal
Current approval: BSL1 (vectorless systems, plasmid and AAV vectors); BSL2 (lentiviral and AAV vectors with growth control genes); BSL2 (human-derived substances); ABSL1 (transgenic mice and frogs); ABSL1 (mice administered AAV or plasmid vectors). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Added new gene elements in plasmid (BSL1), AAV (BSL1), lentivirus (BSL2), and vectorless systems (BSL1), and additional transgenic mice (ABSL1). Removed work with transgenic frogs.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

20. IBCA00001135_AR05
Coleman, Rhima – Amendment
Current approval: BSL1 (plasmid vectors); BSL2 (lentivirus vectors); BSL2 (human-derived substances); ABSL2 for the duration (rodents administered human-derived substances or rDNA modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Added administration of lentivirus vectors to mice via category 1 ROAs (ABSL1).
Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

21. IBCA00001188_AR04
Rao, Rajesh – Amendment
Current approval: BSL1 (plasmid and baculoviral vectors); BSL2 (lentiviral and MSCV vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Added work with additional plasmid vectors (BSL1) and work with adenoviral vectors (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application and favorable review from one reviewer.

22. IBCA00001214_AR04
Albert, Devon – Amendment
Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.
Changes: Changed PI (previously Reed).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon favorable review from one reviewer.

23. IBCA00001399_AR07
Beard, Daniel – Amendment
Current approval: BSL1 (plasmid vectors); BSL2 (human-derived substances); BSL1 (animal-derived substances: swine); ABSL1 (transgenic rats). No work involving infectious agents, biological toxins, or plants.
Changes: Updated risk mitigation practices (BSL2).
Consensus: The committee agreed with the reviewers that the described BSL2 risk mitigation practices are appropriate.

24. IBCA00001677_AR06
O'Dwyer, David – Amendment
Current approval: BSL2 (RG2 bacteria); BSL2 (LPS and Diphtheria toxin); BSL2 (human- and animal-derived substances from swine); ABSL1 (transgenic mice); ABSL1 (mice administered Diphtheria toxin or LPS); ABSL2 for the duration (mice administered human-derived substances or RG2 bacteria). No work involving rDNA or plants.
Changes: Added administration of Streptococcus mitis to mice (ABSL2 for the duration).
Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

25. IBCA00001827_AR03
Pai, Amit – Renewal
Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon favorable re-review from one reviewer.

26. IBCA00002194_AR01
McNeil, Anne – Renewal

Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

27. IBCA00002232_AR07
Elaimy, Ameer – Amendment
Current approval: Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus and MoLV vectors); BSL2 (Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered Diphtheria toxin, plasmid vectors or rDNA-modified animal cells); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving infectious agents, animal-derived substances, or plants.
Changes: Change PI (Previously Zhang). Updated genetic elements. Added administration of additional non-recombinant human-derived substances (ABSL2 for the duration). Removed work with biological toxins and human blood products. Approval is contingent upon minor edits being made to the application.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

28. IBCA00002386_AR02
McCray, Brett – Renewal
Current approval: BSL1 (plasmid vectors, baculovirus vectors, and vectorless systems); BSL2 (lentivirus vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Added new gene elements in lentivirus vectors (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable review by one reviewer.

29. IBCA00002446_AR04
Hastings, Michelle – Renewal
Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (human-derived substances); BSL2 (animal-derived substances: swine); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems). No work involving infectious agents, biological toxins, or plants.
Changes: Added work with additional human-derived substances (BSL2). Changed the biosafety level of work with animal-derived substances from swine to BSL1.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

30. IBCA00002547_AR01
Parikh, Neehar – Renewal
Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: Changed PI (previously Anna Lok).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

31. IBCA00002768_AR02
Tsou, Eliza – Amendment
Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Added new gene elements in plasmid vectors and vectorless systems (BSL1).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

32. IBCA00003169_AR01
Brown, David – Amendment
Current approval: BSL1 (plasmid and AAV vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered plasmid vectors; rodents administered AAV vectors); ABSL2 for the duration (mice administered human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Changed the biosafety level for AAV vectors with growth control genes to BSL2 and added category 2 route of administration for administration of AAV vectors to rodents (ABSL1, unless the AAV vector expresses a growth control gene, then ABSL2 for 3 days).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

33. IBCA00003209_AR01
Cichewicz II, Robert – Amendment
Current approval: BSL1 (phage vectors). No work involving infectious agents, biological toxins, human or animal-derived substances, animals or plants.
Changes: Added work with human-derived substances (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon favorable review by one reviewer.

34. *This application was tabled.*

35. IBCA00003256
Lei, Ieng Lam - Initial Application
Proposed: BSL1 (plasmid and AAV vectors); BSL2 (human-derived substances); BSL1 (animal-derived substances: swine); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors). No work involving infectious agents, biological toxins, or plants.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

36. IBCA00003258
Spanninga, Sarah - Biotechnicum Core Facility - Initial Application

Proposed: May potentially include work with BSL1/BSL2 (all vectors); BSL2 (infectious agents); BSL2 (human- and animal-derived substances from sheep). No work involving biological toxins, animals or plants.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

> **Motion:** Chris Fenno motioned to approve the (34) IBC applications listed above at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.
> **Second:** Matt Chapman seconded the motion.
> **Vote:** All in favor.

BSL1 Applications

The following BSL1 applications were considered by the committee and voted upon.

37. *This application was tabled.*

38. IBCA00000362_AR04
Nagashima, Mikiko – Amendment
Current approval: BSL1 (plasmid vectors); ABSL1 (transgenic zebrafish). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.
Changes: Changed PI (previously Peter Hitchcock) and added new genes in plasmid vectors (BSL1).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate.

39. IBCA00000707_AR04
Mueller, Jacob – Renewal
Current approval: BSL1 (plasmid, phage, and YAC vectors; vectorless systems); BSL1 (animal-derived substances: deer mice); ABSL1 (transgenic mice). No work involving infectious agents, biological toxins, human-derived substances, or plants.
Changes: Added work with additional plasmid and phage vectors (BSL1).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate.

40. IBCA00000942_AR03
Rothschild, Gideon – Renewal
Current approval: BSL1 (AAV vectors); ABSL1 (transgenic rodents); ABSL1 (rodents administered AAV vectors). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate.

41. IBCA00002432_AR01
Nesvizhskii, Alexey - Proteomics Resource Facility Core – Renewal
Current approval: BSL1 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

42. IBCA00003158_AR01
Zhu, Yunlu – Amendment
Current approval: BSL1 (plasmid vectors and vectorless systems); ABSL1 (transgenic zebrafish); ABSL1 (zebrafish administered plasmid vectors). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.
Changes: Added new gene elements in plasmid vectors and vectorless systems (BSL1).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

> **Motion:** Matt Chapman motioned to approve the (5) IBC applications listed above at the containment levels agreed upon.
> **Second:** Alex Rickard seconded the motion.
> **Vote:** All in favor

Tabled Applications

The following applications were tabled.

34. IBCA00003232
Bhattacharyya, Swati - Initial Application
Proposed: BSL1 (plasmid vectors); BSL2 (lentivirus vectors); BSL2 (human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, animals or plants.
Consensus: Tabled.

37. IBCA00000154
Kotov, Nicholas - Initial Application
Proposed: BSL1 (AAV vectors). No work involving infectious agents, biological toxins, human- or animal-derived substances, animals or plants.
Consensus: Tabled.

6. Matters Arising

There were no matters arising.